1. Home
  2. ATNM vs BHM Comparison

ATNM vs BHM Comparison

Compare ATNM & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • BHM
  • Stock Information
  • Founded
  • ATNM 2000
  • BHM 2022
  • Country
  • ATNM United States
  • BHM United States
  • Employees
  • ATNM N/A
  • BHM N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • BHM Real Estate Investment Trusts
  • Sector
  • ATNM Health Care
  • BHM Real Estate
  • Exchange
  • ATNM Nasdaq
  • BHM Nasdaq
  • Market Cap
  • ATNM 50.2M
  • BHM 51.9M
  • IPO Year
  • ATNM N/A
  • BHM N/A
  • Fundamental
  • Price
  • ATNM $1.51
  • BHM $10.58
  • Analyst Decision
  • ATNM Strong Buy
  • BHM Strong Buy
  • Analyst Count
  • ATNM 2
  • BHM 1
  • Target Price
  • ATNM $4.50
  • BHM $15.00
  • AVG Volume (30 Days)
  • ATNM 160.4K
  • BHM 2.2K
  • Earning Date
  • ATNM 11-13-2025
  • BHM 01-01-0001
  • Dividend Yield
  • ATNM N/A
  • BHM 4.72%
  • EPS Growth
  • ATNM N/A
  • BHM N/A
  • EPS
  • ATNM N/A
  • BHM N/A
  • Revenue
  • ATNM N/A
  • BHM $71,496,000.00
  • Revenue This Year
  • ATNM N/A
  • BHM N/A
  • Revenue Next Year
  • ATNM N/A
  • BHM N/A
  • P/E Ratio
  • ATNM N/A
  • BHM N/A
  • Revenue Growth
  • ATNM N/A
  • BHM 27.87
  • 52 Week Low
  • ATNM $1.03
  • BHM $9.30
  • 52 Week High
  • ATNM $2.41
  • BHM $15.60
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 43.91
  • BHM 28.27
  • Support Level
  • ATNM $1.47
  • BHM $11.00
  • Resistance Level
  • ATNM $1.59
  • BHM $11.98
  • Average True Range (ATR)
  • ATNM 0.08
  • BHM 0.26
  • MACD
  • ATNM -0.00
  • BHM -0.04
  • Stochastic Oscillator
  • ATNM 28.95
  • BHM 13.80

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About BHM Bluerock Homes Trust Inc.

Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.

Share on Social Networks: